200 related articles for article (PubMed ID: 37680638)
1. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
Carbone ML; Capone A; Guercio M; Reddel S; Silvestris DA; Lulli D; Ramondino C; Peluso D; Quintarelli C; Volpe E; Failla CM
Front Immunol; 2023; 14():1197630. PubMed ID: 37680638
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
4. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
6. Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
Yu IS; Wee K; Williamson L; Titmuss E; An J; Naderi-Azad S; Metcalf C; Yip S; Horst B; Jones SJM; Paton K; Nelson BH; Marra M; Laskin JJ; Savage KJ
Melanoma Res; 2022 Aug; 32(4):278-285. PubMed ID: 35726793
[TBL] [Abstract][Full Text] [Related]
7. Networks of CD8
Fukuda K
Front Immunol; 2022; 13():866703. PubMed ID: 35432377
[TBL] [Abstract][Full Text] [Related]
8. IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.
Willemsen M; Krebbers G; Tjin EPM; Willemsen KJ; Louis A; Konijn VAL; Narayan VS; Post NF; Bakker WJ; Melief CJM; Bekkenk MW; Luiten RM
Exp Dermatol; 2022 Apr; 31(4):556-566. PubMed ID: 34758170
[TBL] [Abstract][Full Text] [Related]
9. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
Edmondson LA; Smith LV; Mallik A
J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
[TBL] [Abstract][Full Text] [Related]
12. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
13. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.
Dousset L; Pacaud A; Barnetche T; Kostine M; Dutriaux C; Pham-Ledard A; Beylot-Barry M; Gérard E; Prey S; Andreu N; Boniface K; Seneschal J
JAAD Int; 2021 Dec; 5():112-120. PubMed ID: 34712997
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML; Madonna G; Capone A; Bove M; Mastroeni S; Levati L; Capone M; Ascierto PA; De Galitiis F; D'Atri S; Fortes C; Volpe E; Failla CM
Sci Rep; 2022 Mar; 12(1):5448. PubMed ID: 35361879
[TBL] [Abstract][Full Text] [Related]
15. Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy.
Jarvis EM; Collings S; Authier-Hall A; Dasyam N; Luey B; Nacey J; Painter GF; Delahunt B; Hermans IF; Weinkove R
Front Immunol; 2021; 12():748741. PubMed ID: 34737749
[TBL] [Abstract][Full Text] [Related]
16. Histological regression in primary melanoma and drug-related immune reaction towards metastatic melanoma: Are they associated??
Ribero S
Med Hypotheses; 2020 Oct; 143():110019. PubMed ID: 32645656
[TBL] [Abstract][Full Text] [Related]
17. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
Willemsen M; Melief CJM; Bekkenk MW; Luiten RM
Front Immunol; 2020; 11():579022. PubMed ID: 33240267
[TBL] [Abstract][Full Text] [Related]
19. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies.
Dousset L; Boniface K; Seneschal J
G Ital Dermatol Venereol; 2019 Aug; 154(4):435-443. PubMed ID: 30650959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]